Veeva Systems (VEEV) to Release Earnings on Thursday

Veeva Systems (NYSE:VEEV) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 20th. Analysts expect Veeva Systems to post earnings of $1.95 per share and revenue of $792.37 million for the quarter. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS.Parties can check the company’s upcoming Q3 2026 earningsummary page for the latest details on the call scheduled for Thursday, November 20, 2025 at 5:00 PM ET.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The firm had revenue of $789.08 million for the quarter, compared to analyst estimates of $768.49 million. During the same period in the previous year, the company earned $1.62 earnings per share. Veeva Systems’s revenue for the quarter was up 16.7% compared to the same quarter last year. On average, analysts expect Veeva Systems to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Veeva Systems Trading Down 0.7%

NYSE VEEV opened at $297.11 on Thursday. The company has a market cap of $48.70 billion, a P/E ratio of 61.01, a PEG ratio of 2.22 and a beta of 0.98. The company has a fifty day simple moving average of $288.05 and a 200 day simple moving average of $276.78. Veeva Systems has a 12-month low of $201.54 and a 12-month high of $310.50.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on VEEV. JPMorgan Chase & Co. upgraded shares of Veeva Systems from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $290.00 to $330.00 in a report on Monday, September 8th. Citigroup raised their price target on shares of Veeva Systems from $329.00 to $349.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Raymond James Financial reissued an “outperform” rating and set a $340.00 price objective (up from $310.00) on shares of Veeva Systems in a report on Thursday, August 28th. Mizuho increased their price objective on Veeva Systems from $295.00 to $325.00 and gave the stock an “outperform” rating in a research note on Friday, August 29th. Finally, UBS Group lifted their target price on Veeva Systems from $285.00 to $310.00 and gave the company a “neutral” rating in a research report on Thursday, August 28th. Seventeen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Veeva Systems currently has an average rating of “Moderate Buy” and a consensus price target of $307.58.

Insider Buying and Selling at Veeva Systems

In related news, insider Thomas D. Schwenger sold 3,350 shares of the business’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total value of $1,005,134.00. Following the transaction, the insider directly owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. The trade was a 12.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the sale, the insider owned 25,325 shares of the company’s stock, valued at $7,765,151.50. This trade represents a 19.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 24,665 shares of company stock worth $7,438,000 in the last quarter. 10.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VEEV. Nomura Holdings Inc. increased its stake in shares of Veeva Systems by 6.9% during the 2nd quarter. Nomura Holdings Inc. now owns 2,976 shares of the technology company’s stock worth $857,000 after purchasing an additional 191 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in Veeva Systems by 16.1% during the second quarter. Geneos Wealth Management Inc. now owns 2,554 shares of the technology company’s stock valued at $736,000 after purchasing an additional 354 shares during the period. Headlands Technologies LLC purchased a new stake in Veeva Systems in the second quarter worth $1,038,000. CANADA LIFE ASSURANCE Co increased its position in Veeva Systems by 8.7% in the second quarter. CANADA LIFE ASSURANCE Co now owns 163,432 shares of the technology company’s stock worth $47,108,000 after buying an additional 13,105 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Veeva Systems by 58.7% in the second quarter. Tower Research Capital LLC TRC now owns 668 shares of the technology company’s stock worth $192,000 after buying an additional 247 shares during the last quarter. 88.20% of the stock is owned by institutional investors.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.